Biomedical subjects
Publications and source records attributed to Mayumi Kimura.
By using two PNA (PNA = peptide nucleic acid) additives, one-base gap structure was formed in RNA. Upon treatment of this gap-forming RNA substrate with Lu(III) ion, the phosphodiester linkage at 5'-side of the unpaired nucleotide was mainly cleaved. Promising feature of PNA as a sequence recognizing moiety of man-made RNA cutters was evidenced.
Lipophilic Malassezia species may induce catheter-associated sepsis in premature neonates and immunocompromised patients receiving parenteral lipid emulsions. To assess the participation of lipolytic enzymes in the pathogenesis of this yeast, we cloned a gene encoding the enzyme. A lipolytic enzyme in the culture supernatant of Malassezia pachydermatis was purified 210-fold to homogeneity. The enzyme showed high esterase activity toward p-nitrophenyl octanoate. The cDNA encoding the enzyme was cloned using a degenerate oligonucleotide primer constructed from the N-terminal amino acid sequence. The cDNA consisted of 1582 bp, including an open reading frame encoding 470 amino acids. The first 19 amino acids and the following 13 amino-acid sequence were predicted to be the signal peptides for secretion and prosequence, respectively. The predicted molecular mass of the 438-amino acid mature protein was 48 kDa. Analysis of the deduced amino acid sequence revealed that it contains the consensus motif (Gly-X-Ser-X-Gly), which is conserved among lipolytic enzymes. Homology investigations showed that the enzyme has similarities principally with 11 lipases produced by Candida albicans (29-34% identity) and some other yeast lipases.
To investigate whether a diurnal animal possesses the orexinergic system implicating vigilance and behavior, we examined Fos immunoreactivity (IR) in orexinergic neurons of Korean chipmunks raised under 12h light-dark cycles. Brain tissue, collected at four different zeitgeber times (ZT), was double-labeled with Fos and orexin-A antibodies. There was no difference in the number of orexin-IR neurons in the hypothalamus across all ZTs. However, more orexin-IR neurons expressing Fos-IR were found at ZTs 3 and 9 than ZTs 15 and 21. The results demonstrate circadian variations in the activation of orexin neurons corresponding with locomotor cycles, similarly seen in nocturnal rodents.
Cdc25 activates maturation promoting factor (MPF) and promotes mitosis by removing the inhibitory phosphate from the Tyr-15 of Cdc2 in human cells. In this study, we searched the interacting protein(s) of human Cdc25C using the yeast two-hybrid screen and identified proliferating cell nuclear antigen (PCNA) as an interacting partner of Cdc25C. The interaction between Cdc25C and PCNA was confirmed in vitro and in vivo. Co-immunoprecipitation analyses using human T cell line, Jurkat, further revealed that Cdc25C interacted with PCNA transiently when cells began to enter mitosis. Immunofluorescence analysis also showed that Cdc25C and PCNA were transiently co-localized in the nucleus at the beginning of M phase. Together with the previous observations of the interaction between various cdc/cyclin and PCNA, our findings strongly suggested a potential role of PCNA at the G2 to M phase transition of cell cycle.
Although orexin was found to promote food intake, recent reports proposed its involvement in the regulation of vigilance. To study the mechanism of how orexin affects arousal, we analyzed glutamate (GLU) release from the locus coeruleus (LC) in rats after systemic injection of orexin-A. Baseline levels of orexin-A in the LC were significantly higher during the dark period than the light period. Intravenous administration of orexin-A increased GLU levels as well as orexin in the LC, simultaneously promoting wakefulness. These results suggest that increases in GLU release may reflect the arousal-inducing effects of orexin.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a crucial cytokine for establishing pregnancy. It has been demonstrated previously in rats that sleep increases during early pregnancy and that centrally administered GM-CSF promotes both rapid eye movement (REM) and non-REM sleep. Therefore, whether GM-CSF is involved in pregnancy-enhanced sleep was investigated using the anti-GM-CSF antibody. Female rats received an intracerebroventricular infusion of either anti-GM-CSF or control IgG (10 microg each) for four nights from the first day of pregnancy (PD1-PD4). Although sleep amounts on PD1 were not affected, anti-GM-CSF decreased non-REM and REM sleep significantly during PD2-PD4 compared with the control baseline of the IgG group. The results demonstrated that anti-GM-CSF treatment suppresses pregnancy-enhanced sleep, suggesting that GM-CSF contributes to sleep regulation during pregnancy.
Explore the source record for details and available documents.